Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, today announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors. An experienced biopharma executive, Ms. Chhabra Karson will lend her business, scientific and operational expertise towards helping Harness achieve its next phase of growth as it advances its oligonucleotide-based platform for controlled upregulation of CNS targets and its lead programme in Huntington's disease. Ms. Chhabra Ka

BOSTON, Dec. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December 22, 2020 (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated August 22, 2020, as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned s

Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis plans to adjourn its special meeting of stockholders to December 22, 2020 BOSTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, and Proteostasis Therapeutics, Inc. (Nasdaq: PTI) today announced that Proteostasis has entered into a definitive agreement for the sale of its Common Stock in a private placement led by Fidelity

SC 13G - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)

8-K - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)

D - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)

3 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)

SC 13G - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)

SC 13D - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)

SC 13G - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)

8-K - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)

4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)

4 - YUMANITY THERAPEUTICS, INC. (0001445283) (Issuer)

Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, today announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors. An experienced biopharma executive, Ms. Chhabra Karson will lend her business, scientific and operational expertise towards helping Harness achieve its next phase of growth as it advances its oligonucleotide-based platform for controlled upregulation of CNS targets and its lead programme in Huntington's disease. Ms. Chhabra Ka